Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer

We have previously shown that aberrant promoter methylation of ZNF331 is a potential biomarker for colorectal cancer detection with high sensitivity (71%) and specificity (98%). This finding was recently confirmed by others, and it was additionally suggested that promoter methylation of ZNF331 was a...

Descripción completa

Detalles Bibliográficos
Autores principales: Vedeld, Hege Marie, Nesbakken, Arild, Lothe, Ragnhild A., Lind, Guro E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975481/
https://www.ncbi.nlm.nih.gov/pubmed/29854011
http://dx.doi.org/10.1186/s13148-018-0503-2
_version_ 1783326993018781696
author Vedeld, Hege Marie
Nesbakken, Arild
Lothe, Ragnhild A.
Lind, Guro E.
author_facet Vedeld, Hege Marie
Nesbakken, Arild
Lothe, Ragnhild A.
Lind, Guro E.
author_sort Vedeld, Hege Marie
collection PubMed
description We have previously shown that aberrant promoter methylation of ZNF331 is a potential biomarker for colorectal cancer detection with high sensitivity (71%) and specificity (98%). This finding was recently confirmed by others, and it was additionally suggested that promoter methylation of ZNF331 was an independent prognostic biomarker for colorectal cancer (n = 146). In the current study, our initial colorectal cancer sample series was extended to include a total of 423 cancer tissue samples. Aberrant promoter methylation was found in 71% of the samples, thus repeatedly suggesting the biomarker potential of ZNF331 for detection of colorectal cancer. Furthermore, multivariate Cox’s analysis indicated a trend towards inferior overall survival for colorectal cancer patients with aberrant methylation of ZNF331.
format Online
Article
Text
id pubmed-5975481
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59754812018-05-31 Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer Vedeld, Hege Marie Nesbakken, Arild Lothe, Ragnhild A. Lind, Guro E. Clin Epigenetics Short Report We have previously shown that aberrant promoter methylation of ZNF331 is a potential biomarker for colorectal cancer detection with high sensitivity (71%) and specificity (98%). This finding was recently confirmed by others, and it was additionally suggested that promoter methylation of ZNF331 was an independent prognostic biomarker for colorectal cancer (n = 146). In the current study, our initial colorectal cancer sample series was extended to include a total of 423 cancer tissue samples. Aberrant promoter methylation was found in 71% of the samples, thus repeatedly suggesting the biomarker potential of ZNF331 for detection of colorectal cancer. Furthermore, multivariate Cox’s analysis indicated a trend towards inferior overall survival for colorectal cancer patients with aberrant methylation of ZNF331. BioMed Central 2018-05-29 /pmc/articles/PMC5975481/ /pubmed/29854011 http://dx.doi.org/10.1186/s13148-018-0503-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Short Report
Vedeld, Hege Marie
Nesbakken, Arild
Lothe, Ragnhild A.
Lind, Guro E.
Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer
title Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer
title_full Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer
title_fullStr Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer
title_full_unstemmed Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer
title_short Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer
title_sort re-assessing znf331 as a dna methylation biomarker for colorectal cancer
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975481/
https://www.ncbi.nlm.nih.gov/pubmed/29854011
http://dx.doi.org/10.1186/s13148-018-0503-2
work_keys_str_mv AT vedeldhegemarie reassessingznf331asadnamethylationbiomarkerforcolorectalcancer
AT nesbakkenarild reassessingznf331asadnamethylationbiomarkerforcolorectalcancer
AT lotheragnhilda reassessingznf331asadnamethylationbiomarkerforcolorectalcancer
AT lindguroe reassessingznf331asadnamethylationbiomarkerforcolorectalcancer

Ejemplares similares